Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart J C, Najib J, Duriez P, Staels B
U.325 INSERM, Département d'Athérosclérose, Institut Pasteur de Lille, Lille, France.
Circ Res. 1999 Sep 3;85(5):394-402. doi: 10.1161/01.res.85.5.394.
Endothelin-1 (ET-1), a 21-amino acid vasoactive peptide mainly produced by vascular endothelial cells, is involved in the regulation of vascular tone and smooth muscle cell proliferation. Peroxisome proliferator-activated receptors (PPARs), key players in lipid and glucose metabolism, have been implicated in metabolic disorders that are predisposing to atherosclerosis. Because of the potential role of ET-1 in vascular disorders such as hypertension and atherosclerosis, we investigated the regulation of ET-1 expression by PPAR activators. Western blot and reverse transcription-polymerase chain reaction analyses demonstrated that both PPARalpha and PPARgamma are expressed in human coronary artery endothelial cells as well as in endothelial cell lines such as HMEC-1 and ECV304. In bovine aortic endothelial cells and HMEC-1 cells, both PPARalpha and PPARgamma ligands inhibited thrombin-induced ET-1 secretion, whereas basal ET-1 secretion was only slightly suppressed. Reverse transcription-polymerase chain reaction experiments showed that this inhibition of ET-1 production occurs at the gene expression level. Using transient transfection assays, we demonstrated that PPARs downregulate thrombin-activated transcription of the human ET-1 promoter. Transactivation studies with c-Jun and c-Fos expression plasmids indicated that PPARs negatively interfere with the activator protein-1 signaling pathway, which mediates thrombin activation of ET-1 gene transcription. Furthermore, electrophoretic mobility shift assays demonstrated that PPAR activators reduce the thrombin-stimulated binding activity of bovine aortic endothelial cell nuclear extracts as well as c-Jun binding to an activator protein-1 consensus site. Taken together, these data indicate that (1) both PPARalpha and PPARgamma are expressed in human vascular endothelial cells and (2) PPAR activators inhibit thrombin-induced ET-1 biosynthesis, indicating a novel role for PPARs in vascular endothelial function.
内皮素 -1(ET-1)是一种主要由血管内皮细胞产生的21个氨基酸的血管活性肽,参与血管张力调节和平滑肌细胞增殖。过氧化物酶体增殖物激活受体(PPARs)是脂质和葡萄糖代谢的关键调节因子,与易导致动脉粥样硬化的代谢紊乱有关。鉴于ET-1在高血压和动脉粥样硬化等血管疾病中的潜在作用,我们研究了PPAR激活剂对ET-1表达的调控。蛋白质免疫印迹法和逆转录 - 聚合酶链反应分析表明,PPARα和PPARγ在人冠状动脉内皮细胞以及HMEC-1和ECV304等内皮细胞系中均有表达。在牛主动脉内皮细胞和HMEC-1细胞中,PPARα和PPARγ配体均抑制凝血酶诱导的ET-1分泌,而基础ET-1分泌仅略有抑制。逆转录 - 聚合酶链反应实验表明,这种对ET-1产生的抑制发生在基因表达水平。通过瞬时转染实验,我们证明PPARs可下调凝血酶激活的人ET-1启动子转录。用c-Jun和c-Fos表达质粒进行的反式激活研究表明,PPARs负向干扰介导ET-1基因转录的凝血酶激活的激活蛋白-1信号通路。此外,电泳迁移率变动分析表明,PPAR激活剂可降低凝血酶刺激的牛主动脉内皮细胞核提取物的结合活性以及c-Jun与激活蛋白-1共有位点的结合。综上所述,这些数据表明:(1)PPARα和PPARγ在人血管内皮细胞中均有表达;(2)PPAR激活剂抑制凝血酶诱导的ET-1生物合成,表明PPARs在血管内皮功能中具有新的作用。